After the USFDA revoked approval for two drugs that were meant to be key to Ranbaxy's fortunes going forward, sellers were ready with their bids before the bourses opened for trade. Stock slumped as much as 5% on the last trading day of the previous week before staging a recovery. Why is it such a setback for the company? And how is Ranbaxy’s loss, Dr Reddy’s gain? ET NOW gets you the report.
